Sleep apnea research highlights CPAP and new drug treatments

Obstructive sleep apnea (OSA) is a respiratory disorder characterized by the narrowing or closure of soft tissues in the throat during sleep, leading to breathing pauses that reduce blood oxygen levels. In Germany, the condition affects approximately 30 percent of men and 13 percent of women. Symptoms include loud snoring, frequent awakenings, daytime fatigue, and increased risks of cardiovascular disease.

Standard treatment remains Continuous Positive Airway Pressure (CPAP) therapy, which uses a mask to maintain airway openness. However, patient compliance can be hindered by discomfort. Emerging research suggests that weight-loss medications, specifically tirzepatide, may show promise in reducing breathing disturbances for adults with both obesity and moderate to severe sleep apnea.

In certain jurisdictions, such as Germany, individuals with sleep apnea may qualify for a degree of disability (GdB) depending on the severity and specific medical requirements.